38353101|t|Adjunctive silymarin supplementation and its effects on disease severity, oxidative stress, and inflammation in patients with Alzheimer's disease.
38353101|a|BACKGROUND: Brain tissue in Alzheimer's patients is exposed to oxidative stress. Silymarin is an adjunct drug that has anti-inflammatory and antioxidant properties. OBJECTIVE: This study aimed to evaluate the effect of silymarin on biomarkers of oxidative stress, inflammation, and disease severity in Alzheimer's patients. METHODS: This randomized, single-blind clinical trial study was performed on 33 patients with Alzheimer's disease (AD) whose disease was confirmed by DSM-5 criteria and by brain imaging. Patients in the case group received three 250 mg silymarin capsules daily (each containing 150 mg silymarin), as an adjunctive medication in addition to the routine medication regimen. In the placebo group (control), patients received the same amount of placebo. All patients underwent Mini Mental State Exam (MMSE) and a panel of blood tests including malondialdehyde, neopterin, catalase, paraoxonase-1, total oxidative status, and total antioxidant capacity to reevaluate the changes pre/postintervention at the end of the trimester. RESULTS: The catalase and MDA serum levels after the adjunctive silymarin treatment decreased significantly (Catalasebefore silymarin = 9.29 +- 7.02 vs Catalaseafter silymarin = 5.32 +- 2.97, p = 0.007 and MDAbefore silymarin = 4.29 +- 1.90 vs MDAafter silymarin = 1.66 +- 0.84, p < 0.001) while MMSE increased notably (MMSEbefore silymarin = 10.39 +- 6.42 vs MMSEafter silymarin = 13.37 +- 6.81, p < 0.001). CONCLUSION: Silymarin can be effective as an adjunct drug and a powerful antioxidant in reducing oxidative stress and improving the course of AD.
38353101	11	20	silymarin	Chemical	MESH:D012838
38353101	96	108	inflammation	Disease	MESH:D007249
38353101	112	120	patients	Species	9606
38353101	126	145	Alzheimer's disease	Disease	MESH:D000544
38353101	175	186	Alzheimer's	Disease	MESH:D000544
38353101	187	195	patients	Species	9606
38353101	228	237	Silymarin	Chemical	MESH:D012838
38353101	271	283	inflammatory	Disease	MESH:D007249
38353101	366	375	silymarin	Chemical	MESH:D012838
38353101	411	423	inflammation	Disease	MESH:D007249
38353101	449	460	Alzheimer's	Disease	MESH:D000544
38353101	461	469	patients	Species	9606
38353101	551	559	patients	Species	9606
38353101	565	584	Alzheimer's disease	Disease	MESH:D000544
38353101	586	588	AD	Disease	MESH:D000544
38353101	658	666	Patients	Species	9606
38353101	707	716	silymarin	Chemical	MESH:D012838
38353101	756	765	silymarin	Chemical	MESH:D012838
38353101	875	883	patients	Species	9606
38353101	925	933	patients	Species	9606
38353101	1011	1026	malondialdehyde	Chemical	MESH:D008315
38353101	1028	1037	neopterin	Chemical	MESH:D019798
38353101	1039	1047	catalase	Gene	847
38353101	1049	1062	paraoxonase-1	Gene	5444
38353101	1208	1216	catalase	Gene	847
38353101	1221	1224	MDA	Chemical	MESH:D015104
38353101	1259	1268	silymarin	Chemical	MESH:D012838
38353101	1304	1328	Catalasebefore silymarin	Chemical	-
38353101	1347	1360	Catalaseafter	Chemical	-
38353101	1361	1370	silymarin	Chemical	MESH:D012838
38353101	1401	1410	MDAbefore	Chemical	-
38353101	1411	1420	silymarin	Chemical	MESH:D012838
38353101	1439	1447	MDAafter	Chemical	-
38353101	1448	1457	silymarin	Chemical	MESH:D012838
38353101	1526	1535	silymarin	Chemical	MESH:D012838
38353101	1565	1574	silymarin	Chemical	MESH:D012838
38353101	1616	1625	Silymarin	Chemical	MESH:D012838
38353101	1746	1748	AD	Disease	MESH:D000544
38353101	Negative_Correlation	MESH:D012838	MESH:D007249
38353101	Negative_Correlation	MESH:D012838	847
38353101	Negative_Correlation	MESH:D008315	MESH:D012838
38353101	Negative_Correlation	MESH:D012838	MESH:D000544
38353101	Negative_Correlation	MESH:D012838	MESH:D015104

